Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
85447 trials found · Page 50 of 4273
-
New hope for Tough-to-Treat lung cancer: experimental drug enters final testing phase
Disease control Recruiting nowThe goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (ES-SCLC). The primary objectives of this …
Phase: PHASE3 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Could this pill let Sun-Sensitive patients finally enjoy daylight?
Disease control Recruiting nowThe goal of this clinical trial is to learn if bitopertin works and is safe to treat EPP or XLP in participants 12 years or older. The main questions it aims to answer are: * Whether bitopertin increases pain-free sunlight exposure after 6 months of treatment in participants wit…
Phase: PHASE3 • Sponsor: Disc Medicine, Inc • Aim: Disease control
Last updated Apr 06, 2026 14:18 UTC
-
Experimental cell therapy targets Tough-to-Treat cancers
Disease control Recruiting nowThis is a single-arm, open-label, exploratory clinical study to evaluate the safety and preliminary efficacy of Anti-HER2 CAR-T cell injection in patients with HER2-positive advanced malignant solid tumors.
Phase: NA • Sponsor: UTC Therapeutics Inc. • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
New Two-Pronged attack tested for Tough-to-Treat blood cancers
Disease control Recruiting nowThis phase Ib/II trial evaluates the safety, optimal dose, and efficacy of the combination of epcoritamab and ibrutinib in treating patients with aggressive B-cell non-Hodgkin lymphoma that has come back (relapsed) or responded to previous treatment (refractory). Epcoritamab, a b…
Phase: PHASE1, PHASE2 • Sponsor: Yazeed Sawalha • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New bridge therapy aims to get more patients to potentially curative CAR-T treatment
Disease control Recruiting nowThis phase II trial tests the effectiveness of golcadomide and rituximab as bridging treatment before chimeric antigen receptor (CAR) T-cell therapy in patients with aggressive B-cell non-Hodgkin lymphoma that has come back after a period of improvement (relapsed) or that has not…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Apr 22, 2026 16:00 UTC
-
AI reads baby poop to predict Life-Threatening gut disease
Diagnosis Recruiting nowPrematurity affects around 7% of births in France. Necrotizing enterocolitis (NEC) is a dreaded digestive complication. It is responsible for a mortality rate ranging from 15 to 40%, a rate that has remained stable in recent years, and for medium- and long-term digestive and neur…
Phase: NA • Sponsor: University Hospital, Clermont-Ferrand • Aim: Diagnosis
Last updated Apr 24, 2026 03:26 UTC
-
Direct-to-Brain chemo trial aims to tackle deadliest brain cancer
Disease control Recruiting nowThe goal of this clinical trial is to learn if a combined treatment approach can treat glioblastoma (GBM) with ventricular invasion or meningeal metastasis in adults. The main questions it aims to answer are: Does the combined treatment of radical radiotherapy, the Stupp regimen…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University • Aim: Disease control
Last updated Apr 13, 2026 20:18 UTC
-
Experimental cell therapy targets Tough-to-Treat lupus
Disease control Recruiting nowThis investigator-initiated trial aims to evaluate the safety and efficacy of universal anti-CD70 CAR-T (CHT101) in patients with relapsed refractory systemic lupus erythematosus.
Phase: EARLY_PHASE1 • Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School • Aim: Disease control
Last updated Apr 09, 2026 19:31 UTC
-
New hope to stop lung Cancer's return after surgery
Disease control Recruiting nowThis phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 21, 2026 12:43 UTC
-
Groundbreaking neck surgery trial offers new hope for halting Alzheimer's
Disease control Recruiting nowAlzheimer's disease (AD), one of the most common causes of dementia in Singapore and the developed world, is a neurodegenerative disorder with high socioeconomic impact. Accumulation of neurotoxic proteins (ie. amyloid, tau) are purported to lead to neuroinflammation, synaptic dy…
Phase: NA • Sponsor: Vincent Tay Khwee Soon • Aim: Disease control
Last updated Apr 20, 2026 16:16 UTC
-
New cell therapy trial offers hope for kids with tough cancers
Disease control Recruiting nowA Phase 1 clinical trial to evaluate the safety and early efficacy of CAR T-cells with IL-7Ra signal targeting B7H3 in children with solid tumors patients after complete standard treatments.
Phase: PHASE1 • Sponsor: Chulalongkorn University • Aim: Disease control
Last updated Apr 23, 2026 12:43 UTC
-
Could a single infusion free diabetics from daily insulin shots?
Disease control Recruiting nowThis study will evaluate the efficacy, safety, and tolerability of VX-880 in participants with Type 1 Diabetes (TID) with a kidney transplant.
Phase: PHASE3 • Sponsor: Vertex Pharmaceuticals Incorporated • Aim: Disease control
Last updated Apr 24, 2026 03:26 UTC
-
New hope for Tough-to-Treat lung cancer: experimental drug takes on chemo in major trial
Disease control Recruiting nowTo evaluate the efficacy and safety of SYS6010 versus platinum-based chemotherapy in participants with EGFR-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC)
Phase: PHASE3 • Sponsor: CSPC Megalith Biopharmaceutical Co.,Ltd. • Aim: Disease control
Last updated Apr 06, 2026 14:14 UTC
-
New combo aims to slash chemo side effects in kids with leukemia
Disease control Recruiting nowThis prospective clinical trial evaluates the effectiveness and safety of "chemotherapy-light" regimen incorporating the third-generation TKI olverembatinib, the bi-specific CD3/CD19 T cell engager blinatumomab, and the BCL-2 selective inhibitor venetoclax for newly diagnosed ped…
Phase: PHASE3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Apr 24, 2026 03:27 UTC
-
Personalized gene therapy aims to heal debilitating skin wounds
Disease control OngoingThe purpose of this study is to determine whether administration of D-Fi in addition to standard of care improves wound healing as compared to standard of care alone (control) in children, adolescents, and adults with Dystrophic Epidermolysis Bullosa.
Phase: PHASE3 • Sponsor: Castle Creek Biosciences, LLC. • Aim: Disease control
Last updated Apr 17, 2026 16:11 UTC
-
Race against time: new device aims to yank Stroke-Causing clots faster
Disease control Recruiting nowThe goal of this clinical trials is to demonstrate the safety and effectiveness for the RapidPulseTM Aspiration System in patients experiencing acute ischemic stroke within 8 hours of symptom onset or last seen normal. Subjects will undergo mechanical thrombectomy (a procedure to…
Phase: NA • Sponsor: RapidPulse, Inc • Aim: Disease control
Last updated Apr 20, 2026 16:18 UTC
-
New drug combo targets hard-to-treat lung cancer in major trial
Disease control Recruiting nowThe main purpose of this study is to assess if olomorasib in combination with pembrolizumab is more effective than the pembrolizumab and placebo combination in part A in participants with resected KRAS G12C-mutant NSCLC and to assess if olomorasib in combination with durvalumab i…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
New hope for Tough-to-Treat head and neck cancers
Disease control Recruiting nowThis phase III trial compares the effect of adding cetuximab to pembrolizumab versus pembrolizumab alone in treating patients with head and neck squamous cell carcinoma (HNSCC) that has come back after a period of improvement (recurrent) and/or that has spread from where it first…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 16, 2026 13:01 UTC
-
New hope for hard-to-treat endometrial cancer: targeted therapy plus immunotherapy tested in major trial
Disease control Recruiting nowDESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by B…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 23, 2026 12:45 UTC
-
First-in-Human trial tests engineered immune cells against deadly pancreatic cancer
Disease control Recruiting nowThis is a single-arm, open-label clinical study to evaluate the safety, tolerability and preliminary efficacy of IX001 TCR-T injection in advanced pancreatic cancer patients with KRAS G12V mutation.
Phase: PHASE1 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 22, 2026 15:59 UTC